Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 76 to 77 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.
Abstract: The present invention relates to a method using a composition for permeabilizing microorganism walls for counting and detecting in a targeted manner the microorganisms on a membrane. The invention also relates to a kit and to probes that are suitable for carrying out the method.
Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 68 to 69 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.
Abstract: Methods and materials involved in diagnosing SLE are provided herein. The methods and materials can be used to diagnose SLE and/or assess a mammal's susceptibility to develop SLE, based on the presence or absence of one or more IRF-5 variants.
Type:
Grant
Filed:
September 23, 2009
Date of Patent:
April 3, 2012
Assignees:
Regents of the University of Minnesota, General Hospital Corporation
Inventors:
Timothy W. Behrens, Robert R. Graham, David Altshuler
Abstract: The invention provides methods to detect C. difficile in biological samples using real-time PCR. Primers and probes for the detection of C. difficile are provided by the invention. Articles of manufacture containing such primers and probes for detecting C. difficile are further provided by the invention.
Type:
Grant
Filed:
February 6, 2009
Date of Patent:
January 24, 2012
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Franklin R. Cockerill, III, Thomas F. Smith, Jon E. Rosenblatt, Lynne M. Sloan
Abstract: Disclosed is a method for determining the presence of Mycobacterium avium complex nucleic acids in a biological sample. In particular, the IS1245 gene of M. avium and the DT1 gene of M. intracellulare are detected, preferably following amplification. In addition, the method distinguishes between species of M. avium and M. intracellulare. Also described are oligonucleotides that can be used as primers to amplify target genes such as IS1245 and DT1 genes and as probes as well as kits containing the oligonucleotides.
Abstract: The invention relates to methods and reagents for the determination of telomere length in tissue sections by the single cell telomeric mapping technique based on a fluorescent in situ hybridization step using a telomere-specific probe and an interpolation step using a standard curve correlating fluorescent intensity and telomere length obtained from a collection of cell lines of known telomere length. The invention further relates to methods for the identification of stem cell niches within tissues and for the identification of compounds capable of triggering stem cell mobilization using the telomere length as criteria for the identification of stem cells and which rely on the single cell telomeric mapping technique of the invention.
Type:
Grant
Filed:
May 12, 2008
Date of Patent:
December 27, 2011
Assignee:
Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III
Abstract: The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.
Type:
Grant
Filed:
November 19, 2010
Date of Patent:
December 27, 2011
Assignee:
Theranostics Laboratory
Inventors:
Patrick A. Gladding, Arzu Gunes, Marja-Liisa Dahl, Mark W. Webster
Abstract: An infectious etiologic agent detection probe set which detects an infectious etiologic agent gene, includes a plurality of kinds of probes including oligonucleotide having base sequences selected from each of a plurality of groups selected from a first group including base sequences of SEQ ID Nos. 1 to 14 and complementary sequences thereof, a second group including base sequences of SEQ ID Nos. 15 to 24 and complementary sequences thereof, a third group including base sequences of SEQ ID Nos. 25 to 36 and complementary sequences thereof, a fourth group including base sequences of SEQ ID Nos. 37 to 47 and complementary sequences thereof, a fifth group including base sequences of SEQ ID Nos. 48 to 57 and complementary sequences thereof, a sixth group including base sequences of SEQ ID Nos. 58 to 68 and complementary sequences thereof, a seventh group including base sequences of SEQ ID Nos. 69 to 77 and complementary sequences thereof, an eighth group including base sequences of SEQ ID Nos.
Abstract: The present invention relates to oligonucleotide primers and primer sets that can be used to identify the bacterial pathogen Acidovorax avenae subsp. citrulli in a test sample.
Abstract: The present invention is directed to BAP28 polypeptides. BAP28 cDNA sequences encoding BAP28 polypeptides, to the genomic DNA sequence of the BAP28 gene as well as to regulatory regions located at the 5?- and 3?-ends of the BAP28 coding region. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the BAP28 gene useful in genetic analysis. The invention concerns an association of the BAP28-related biallelic markers with prostate cancer. Therefore, the invention contemplates the diagnostic and treatment methods of prostate cancer.
Abstract: A polynucleotide consisting of the base sequence of SEQ ID NO: 2, or a complementary strand thereto, wherein the X is one of the group being defined by the bases A, C or T. A primer and a probe specific for that polynucleotide, wherein the primer and/or probe contains at the least 10 consecutive nucleotides, and finally use of the probe for proving parkinsonism inheritance.
Type:
Grant
Filed:
April 30, 2009
Date of Patent:
August 9, 2011
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Jan O Aasly, Zbigniew K Wszolek, Matthew J Farrer
Abstract: The present invention provides methods and kits for identifying an increased risk of developing cancer in a subject. The methods include analyzing a first biological sample, such as a blood sample, from the subject for loss of imprinting of the IGF2 gene. According to the methods a loss of imprinting is indicative of an increased risk of developing cancer. The method can include analyzing genomic DNA from the sample for altered methylation of the IGF2 or the H19 gene. The altered methylation for example includes hypomethylation of a differentially methylated region of IGF2, corresponding to SEQ ID NO:1 and/or a polymorphism or fragment thereof, or hypomethylation of a differentially methylated region of H19 corresponding to SEQ ID NO:6, or a polymorphism, or fragment thereof. In certain aspects, hypomethylation of the H19 DMR or the IGF2 DMR indicates an increased risk of developing colorectal cancer.
Type:
Grant
Filed:
July 28, 2003
Date of Patent:
July 19, 2011
Assignee:
The Johns Hopkins University School of Medicine
Abstract: The present invention relates to a genotyping kit for diagnosis of detecting the human papillomavirus (HPV) infection, probes for genotyping the HPV, and DNA chips including the probes. Also, the present invention relates to a method for diagnosis of HPV infection.
Type:
Grant
Filed:
September 18, 2001
Date of Patent:
November 27, 2007
Assignee:
Biomedlab Corporation
Inventors:
Sung-Wook Yoon, Tae-Shin Park, Jeong-Mi Kim, Mi-Sun Park
Abstract: A method for the identification of human foetal cell nuclei is provided wherein the method involves subjecting chromosomes of cell nuclei to exonucleolytic digestion by an enzyme so as to remove end regions of each chromosome; and detecting the presence of a DNA sequence remaining in foetal DNA but absent from maternal DNA as a result of the digestion process. Once identified, the foetal DNA can be subject to diagnosis for example to detect chromosomal abnormalities.
Abstract: The invention relates to a method for the prediction of the risk potential and/or diagnosis of cancerous diseases or inflammatory intestinal diseases, whereby a DNA sample is tested for the presence of polymorphic UGT1A7 allele. A positive result for a mutation is a positive indication of a sensitivity to cancerous diseases. A prediction of sensitivity to an inflammatory intestinal disease can similarly be made. A PCR amplification of the exon 1, using the DNA sample with subsequent sequence analysis is carried out in the method and the determined sequence compared with that of the wild type and the polymorphic allele. The presence or lack of mutations is monitored by sequencing the corresponding cDNA using automated fluorescent dye sequencing. The test arrangement for requires genetic detection reagents, namely the required primer or cDNAs, on a stationary support in a pre-prepared arrangement or sequence for reading off the results. The recombinant UGT1A7 enzymes are also used for therapeutic purposes.
Abstract: Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a Mexican-American human subject for developing insulin resistance and methods of detecting a lower than normal risk in a Mexican-American human subject for developing insulin resistance or coronary artery disease.
Type:
Grant
Filed:
June 16, 2003
Date of Patent:
November 28, 2006
Assignees:
Cedars-Sinai Medical Center, The Regents of the University of California
Inventors:
Kent D. Taylor, Jerome I. Rotter, Huiying Yang, Willa A. Hsueh, Xiuqing Guo, Leslie J. Raffel, Mark O. Goodarzi
Abstract: The present invention is related to rpoB gene fragments and method for the diagnosis and identification of Mycobacterium tuberculosis and non-lubercuolsis Mycobacterial strains using rpoB gene and it's fragments.
Type:
Grant
Filed:
October 27, 2000
Date of Patent:
October 4, 2005
Inventors:
Hyeyoung Lee, Young Kil Park, Gill-Han Bai, Sang-Jae Kim, Sang-Nae Cho, Yeun Kim, Hee Jung Park
Abstract: Described herein are methods that can be used for diagnosis and prognosis of breast cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in breast cancer are described.
Abstract: Described herein are methods that can be used for diagnosis and prognosis of breast cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in breast cancer are described.